Company release
Nanoform Finland Plc
January 10, 2024
23.00 Finnish time / 22.00 Swedish time
Nanoform Finland Plc – Manager’s transactions – David Rowe
Helsinki, Finland – Manager’s transaction related to Nanoform Finland Plc’s Head of Manufacturing David Rowe’s acceptance of stock options:
Person subject to the notification requirement
Name: David Rowe
Position: Other senior manager
Issuer: Nanoform Finland Oyj
LEI: 743700JJO2NU8LBS1592
Notification type: INITIAL NOTIFICATION
Reference number: 48937/6/6
Transaction date: 2024-01-10
Outside a trading venue
Instrument type: FINANCIAL INSTRUMENT LINKED TO A SHARE OR A DEBT INSTRUMENT
Name of the instrument: Nanoform Finland Oyj stock option 1/2024
Nature of transaction: ACCEPTANCE OF A STOCK OPTION
(X) Made under life insurance policy
Transaction details
(1): Volume: 73720 Unit price: 0 EUR
Aggregated transactions (1):
Volume: 73720 Volume weighted average price: 0 EUR
For further information, please contact:
Albert Haeggström, CFO
albert.haeggstrom@nanoform.com
+358 29 370 0150
For investor relations queries, please contact:
Henri von Haartman
Director of Investor Relations
+46 7686 650 11
About Nanoform
Nanoform is an innovative nanoparticle medicine enabling company. Nanoform works together with pharma and biotech partners globally to provide hope for patients in developing new and improved medicines utilizing Nanoform’s platform technologies. The company focuses on reducing clinical attrition and on enhancing drug molecules’ performance through its nanoforming technologies and formulation services. Nanoform’s capabilities include GMP manufacturing, and its services span the small to large molecule development space with a focus on solving key issues in drug solubility and bioavailability and on enabling novel drug delivery applications. Nanoform’s shares are listed on the Premier-segment of Nasdaq First North Growth Market in Helsinki (ticker: NANOFH) and Stockholm (ticker: NANOFS). Certified Adviser: Danske Bank A/S, Finland Branch, +358 40 744 1900. For more information, please visit www.nanoform.com.